A vaccine to treat dengue fever, the mosquito-borne disease, is the end goal of two companies who have signed an agreement to produce and commercialize a lead candidate in the fight against the disease.
Emergex Vaccines Holding Limited, a clinical-stage biotech company, recently announced that it has agreed a collaboration with the Molecular Biology Institute of Paraná (IBMP) in Brazil.
IBMP is a commercial organization with close links to Fiocruz, the most important national institution for research and production of biopharmaceuticals and vaccines linked to the Ministry of Health in Brazil. It has a commercial track record in the healthcare space in the development, manufacturing, regulatory approval and commercialization of medical diagnostics and medicines in Brazil.
The agreement, once fully executed, will involve a shared clinical development phase as well as allowing IBMP exclusive rights for the commercialization of the vaccine candidates in Brazil. In addition, clinical stage manufacturing of the vaccines will be conducted by Emergex with a transition to commercial scale manufacturing being conducted in the region by IBMP.
The post Companies come together in fight against Dengue Fever appeared first on Labiotech.eu.
© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.